Partnering Strategy
Open to range of models, Global & Regional Deals, JV, Spin-Offs and Optional Deal Arrangements.
Commercialize across 'pharmerging' markets on our own or with partners
In License differentiated pre-clinical/IND stage assets and progress them through clinical POC/Phase II
Explore co-development opportunities with assets that complement Rhizen programs
Support CMC development and commercial supply mo, activities
Monetize our inflammation assets through global out-licensing to partners with deep TA expertise
Our Partners
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics is headquartered in New York City (www.tgtxinc.com)
Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies
